OIP5 was reported to be a component gene in a multigene set predicting the risk of prostate cancer recurrence [38]; its upregulation associates with adverse features in ccRCC and bladder cancer [19,29], supporting a general involvement of OIP5 in urogenital cancers. This evidence concerns the gene OIP5 and prostate carcinoma.